Lista de obras - Murielle Roussel - Dominio Público Uruguay

'Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury'

artículo científico publicado en 2016

A macroglobulinemia with an unusual bone marrow aspect

artículo científico publicado en 2001

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

artículo científico publicado en 2018

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

Aggressive FLC Escape in a Patient with IgD Myeloma.

artículo científico publicado en 2015

An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis

artículo científico publicado en 2014

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

artículo científico publicado en 2013

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

artículo científico publicado en 2012

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.

artículo científico publicado en 2013

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

artículo científico publicado en 2009

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

artículo científico publicado en 2010

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2016

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

scientific article published on 03 May 2019

Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis

artículo científico publicado en 2013

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2013

Crowded bone marrow plasma cells

artículo científico publicado en 2020

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

artículo científico publicado en 2011

DKK1 and sclerostin are early markers of relapse in multiple myeloma.

artículo científico publicado en 2017

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

artículo científico publicado en 2013

Diagnosis of monoclonal gammopathy of renal significance

artículo científico publicado en 2015

Dual-energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma

artículo científico publicado en 2012

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

artículo científico publicado en 2019

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

artículo científico publicado en 2014

Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.

artículo científico publicado en 2013

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis

artículo científico publicado en 2016

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

artículo científico publicado en 2011

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

artículo científico publicado en 2014

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

artículo científico publicado en 2020

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

artículo científico publicado en 2006

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

artículo científico publicado en 2015

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2012

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

artículo científico publicado en 2010

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Maintenance therapy for myeloma: how much, how long, and at what cost?

scientific article published on 01 January 2012

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

artículo científico

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

artículo científico publicado en 2018

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

artículo científico

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

article

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

artículo científico

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

artículo científico publicado en 2014

Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.

artículo científico publicado en 2016

Pomalidomide for multiple myeloma

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

artículo científico publicado en 2013

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2018

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

artículo científico publicado en 2015

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

artículo científico publicado en 2015

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

artículo científico publicado en 2016

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

scientific article published on March 2011

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

artículo científico publicado en 2016

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

artículo científico publicado en 2014

UMOD genetic variations and myeloma cast nephropathy

scientific article published on 15 June 2019

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

artículo científico publicado en 2015

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

artículo científico publicado en 2016

[Multiple bone myelomas]

artículo científico publicado en 2009

[Multiple myeloma treatment]

scientific article published on 01 September 2018

Lista de obras de Murielle Roussel

'Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury'

A macroglobulinemia with an unusual bone marrow aspect

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

Aggressive FLC Escape in a Patient with IgD Myeloma.

An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Crowded bone marrow plasma cells

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience

DKK1 and sclerostin are early markers of relapse in multiple myeloma.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Diagnosis of monoclonal gammopathy of renal significance

Dual-energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Maintenance therapy for myeloma: how much, how long, and at what cost?

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.

Pomalidomide for multiple myeloma

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

UMOD genetic variations and myeloma cast nephropathy

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

[Multiple bone myelomas]

[Multiple myeloma treatment]